全文获取类型
收费全文 | 44991篇 |
免费 | 2712篇 |
国内免费 | 258篇 |
专业分类
耳鼻咽喉 | 388篇 |
儿科学 | 1294篇 |
妇产科学 | 1201篇 |
基础医学 | 5912篇 |
口腔科学 | 938篇 |
临床医学 | 4493篇 |
内科学 | 9830篇 |
皮肤病学 | 880篇 |
神经病学 | 4791篇 |
特种医学 | 1498篇 |
外科学 | 5906篇 |
综合类 | 175篇 |
一般理论 | 19篇 |
预防医学 | 3350篇 |
眼科学 | 767篇 |
药学 | 2773篇 |
1篇 | |
中国医学 | 85篇 |
肿瘤学 | 3660篇 |
出版年
2024年 | 70篇 |
2023年 | 521篇 |
2022年 | 998篇 |
2021年 | 1802篇 |
2020年 | 1056篇 |
2019年 | 1484篇 |
2018年 | 1698篇 |
2017年 | 1190篇 |
2016年 | 1336篇 |
2015年 | 1542篇 |
2014年 | 2120篇 |
2013年 | 2640篇 |
2012年 | 3913篇 |
2011年 | 3901篇 |
2010年 | 1972篇 |
2009年 | 1841篇 |
2008年 | 3110篇 |
2007年 | 2999篇 |
2006年 | 2701篇 |
2005年 | 2673篇 |
2004年 | 2231篇 |
2003年 | 1995篇 |
2002年 | 1766篇 |
2001年 | 225篇 |
2000年 | 156篇 |
1999年 | 229篇 |
1998年 | 301篇 |
1997年 | 222篇 |
1996年 | 198篇 |
1995年 | 180篇 |
1994年 | 154篇 |
1993年 | 121篇 |
1992年 | 84篇 |
1991年 | 75篇 |
1990年 | 62篇 |
1989年 | 41篇 |
1988年 | 39篇 |
1987年 | 34篇 |
1986年 | 31篇 |
1985年 | 31篇 |
1984年 | 38篇 |
1983年 | 19篇 |
1982年 | 39篇 |
1981年 | 24篇 |
1980年 | 21篇 |
1979年 | 9篇 |
1978年 | 12篇 |
1977年 | 12篇 |
1976年 | 8篇 |
1972年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Marco Maruzzo Umberto Basso Eugenio Borsatti Laura Evangelista Filippo Alongi Orazio Caffo Francesca Maines Sara Galuppo Rocco De Vivo Fable Zustovich Dario Palleschi Andrea Zivi Teodoro Sava Mariella Sorarù Roberto Iacovelli Maurizio Nicodemo Susanne Baier Lucia Fratino Vittorina Zagonel 《Clinical genitourinary cancer》2019,17(1):e187-e194
Background
Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.Patients and Methods
We conducted a multicenter retrospective analysis in the Triveneto region of Italy.Results
One hundred fifty-eight patients received radium 223 in our region. After a median follow-up of 9.5 months, 75 patients died. The median overall survival (OS) was 14.2 months, and the median progression-free survival (PFS) was 6.2 months. Seventy-one (45%) patients achieved progression as best response. Thirty-seven (23%) patients stopped the treatment early because of progression. Eastern Cooperative Oncology Group performance status was prognostic for OS (18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1, P = .0062; 0 vs. 2, P = .0002), whereas previous prostatectomy or docetaxel exposure were not. A neutrophil to lymphocytes ratio ≥ 3 significantly impacted OS (18.1 vs. 9.7 months; P < .001) and slightly impacted PFS (6.6 vs. 5.6 months; P = .05). Patients with a baseline alkaline phosphatase (ALP) value ≥ 220 U/L had worse OS and PFS (24.1 vs. 10.5 months; 7.2 vs. 5.5 months; P < .001). Patients with changes in ALP value achieved better OS (P = .029) and PFS (P = .002). There was no difference according to the line of therapy (0 vs. ≥ 1; P = .490). The main grade 3/4 toxicities were anemia, asthenia, and thrombocytopenia.Conclusion
This large real-world report confirms comparable OS and PFS data when compared with the pivotal study, as well as the predictive role of ALP and neutrophil to lymphocytes ratio. The definition of the optimal position of radium 223 in the treatment of metastatic castration-resistant prostate cancer has still to be defined. 相似文献2.
Susan M Domchek Andrea Eisen Kathleen Calzone Jill Stopfer Anne Blackwood Barbara L Weber 《Journal of clinical oncology》2003,21(4):593-601
Breast cancer risk assessment provides an estimation of disease risk that can be used to guide management for women at all levels of risk. In addition, the likelihood that breast cancer risk is due to specific genetic susceptibility (such as BRCA1 or BRCA2 mutations) can be determined. Recent developments have reinforced the clinical importance of breast cancer risk assessment. Tamoxifen chemoprevention as well as prevention studies such as the Study of Tamoxifen and Raloxifene are available to women at increased risk of developing breast cancer. In addition, specific management strategies are now defined for BRCA1 and BRCA2 mutation carriers. Risk may be assessed as the likelihood of developing breast cancer (using risk assessment models) or as the likelihood of detecting a BRCA1 or BRCA2 mutation (using prior probability models). Each of the models has advantages and disadvantages, and all need to be interpreted in context. We review available risk assessment tools and discuss their application. As illustrated by clinical examples, optimal counseling may require the use of several models, as well as clinical judgment, to provide the most accurate and useful information to women and their families. 相似文献
3.
Andrea R Genazzani Hermann P G Schneider Nick Panay Esme A Nijland 《Gynecological endocrinology》2006,22(7):369-375
OBJECTIVES: To identify and describe current women's thoughts about the menopause, hormone treatment (HT) and perceptions about breast cancer. METHODS: Between December 2004 and January 2005, 4201 postmenopausal women in seven European countries were interviewed via a standardized computer-aided telephone interview protocol. RESULTS: Almost all women reported to have experienced climacteric symptoms, and 63% of the women rated them as being severe. Only 52% of women were aware of the benefits of HT for relief of climacteric symptoms. Although 84% felt that severe symptoms should be treated, only 40% had used HT at some point in time. Thirty-four percent of the women preferring treatment with natural products did so because of the risk of breast cancer associated with HT. HT was recognized by 59% of the women as one of the most important contributors to an increased breast cancer risk. Most women received their information about HT and breast cancer risk from the media. CONCLUSIONS: This European survey reveals that the majority of women experience climacteric symptoms but that their decision whether or not to use HT is highly dependent on their concern about breast cancer risk. An increase in knowledge of the benefits and risks of HT is required for women to make appropriate decisions about hormone use. 相似文献
4.
5.
6.
Anthony Spirito Larry Brown James Overholser Gregory Fritz Andrea Bond 《Death Studies》1991,15(3):269-280
The assessment of the medical lethality and intent of suicide attempts has been considered an important area of research for those interested in suicide. The current study examined the usefulness of the Risk-Rescue Rating Scale with 109 adolescent suicide attempters and found a restricted range of variability, which, in turn, resulted in poor interrater reliability on a number of items. Results suggest that the Risk-Rescue Rating Scale is of limited usefulness with adolescents, and alternative approaches to assessing lethality and suicidal intent with this age group are discussed. 相似文献
7.
Andrea Salonia MD Alberto Briganti MD Andrea Gallina MD Giuseppe Zanni MD Federico Dehò MD Patrizio Rigatti MD Francesco Montorsi MD 《Current Sexual Health Reports》2007,4(2):85-90
This article assesses the effects of lower urinary tract symptoms (LUTS), not including urinary incontinence, on the overall
sexual health of women, using literature that includes peer-reviewed articles. This article analyzes a number of studies that
provide data on the prevalence and the predictors of sexual function impairment in women with LUTS, such as urinary urgency
and frequency, overactive bladder syndrome, and interstitial cystitis. Because case studies provide substantial heterogeneity
of outcome measures, this article does not apply meta-analytic techniques to the data. Most of the studies showed that LUTS
can have a negative impact on the sexual health of women, sexual pain disorder being the more frequent complaint among patients
with bladder dysfunctions. 相似文献
8.
Andrea Berger Michelle Sadeh Gabriel Tzur I Avinoam Shuper Liora Kornreich Dov Inbar Ian J Cohen Shalom Michowiz Isaac Yaniv Shlomi Constantini Eli Vakil 《Journal of the International Neuropsychological Society》2005,11(4):482-487
Cerebellar involvement in motor and non-motor sequence learning was examined with serial reaction time tasks (SRT). Our sample consisted of 8 children and adolescents who had undergone surgical removal of a benign posterior fossa tumor (PFT) during childhood. None of them had undergone chemotherapy or cranial radiation therapy (CRT). Ages ranged from 1-11 years at surgery and 9-17 years at testing. The children were tested not earlier than 2.5 years after surgery (M = 5.9 years), enabling brain plasticity and recovery of functions. Their performance was compared with a matched control sample. The PFT group was not impaired in the implicit learning of sequences, as reflected in their performance in blocks with a repeated sequence, both before and after a random block. However, in the perceptual task, their performance deteriorated more than that of the control group when a random block was introduced, suggesting that it was more difficult for the patients to respond flexibly or change their response set when encountering changing task demands. These results are in line with another study by our group on task switching with the same patients. 相似文献
9.
Angelo M. Carella Sandro Nati Paolo Carlier Daniela Pierluigi Domenico Giordano Angela Congiu Gino Santini Daniele Scarpati Salvina Barra Renzo Corvo Vito Vitale Maria R. Raffo Raffaella Cerri Marco Risso Mauro Spriano Renato Vimercati Ester Pungolino Andrea Bacigalupo Eugenio Damasio 《Leukemia & lymphoma》1991,5(1):43-47
Forty consecutive adult patients under the age of 50 with acute non-lymphoblastic leukemia (ANLL) in first complete remission, underwent autologous bone marrow transplantation (ABMT) between March 1984 and April 1990. The conditioning regimen employed included cyclophosphamide and total body irradiation, followed by the administration of unpurged ABMT. The median time from diagnosis to transplant was 7 months (3-15 months), and the median time from complete remission to ABMT was 4 months (range 3-9 months). Twenty-two (51%) patients remain in complete remission 6-81 months (median 24 months) after ABMT.
The causes of death were, recurrent leukemia (11 patients), parenchymal toxicities such as acute respiratory distress syndrome and veno-occlusive disease (3 patients), hemorrhage (2 patients) and infection (2 patients). Eleven patients relapsed after 3-12 months (median 5 months). This study has produced survival data comparable to those of other institutions employing TBI for either allo or autotransplants. 相似文献
The causes of death were, recurrent leukemia (11 patients), parenchymal toxicities such as acute respiratory distress syndrome and veno-occlusive disease (3 patients), hemorrhage (2 patients) and infection (2 patients). Eleven patients relapsed after 3-12 months (median 5 months). This study has produced survival data comparable to those of other institutions employing TBI for either allo or autotransplants. 相似文献
10.
David G Hicks Brian J Yoder Sarah Short Shannon Tarr Nichole Prescott Joseph P Crowe Andrea E Dawson G Thomas Budd Steven Sizemore Muzaffer Cicek Toni K Choueiri Raymond R Tubbs Daniel Gaile Norma Nowak Mary Ann Accavitti-Loper Andra R Frost Danny R Welch Graham Casey 《Clinical cancer research》2006,12(22):6702-6708
PURPOSE: This study aims to determine the effect of loss of breast cancer metastasis suppressor 1 (BRMS1) protein expression on disease-free survival in breast cancer patients stratified by estrogen receptor (ER), progesterone receptor (PR), or HER2 status, and to determine whether loss of BRMS1 protein expression correlated with genomic copy number changes. EXPERIMENTAL DESIGN: A tissue microarray immunohistochemical analysis was done on tumors of 238 newly diagnosed breast cancer patients who underwent surgery at the Cleveland Clinic between January 1, 1995 and December 31, 1996, and a comparison was made with 5-year clinical follow-up data. Genomic copy number changes were determined by array-based comparative genomic hybridization in 47 breast cancer cases from this population and compared with BRMS1 staining. RESULTS: BRMS1 protein expression was lost in nearly 25% of cases. Patients with tumors that were PR negative (P=0.006) or HER2 positive (P=0.039) and <50 years old at diagnosis (P=0.02) were more likely to be BRMS1 negative. No overall correlation between BRMS1 staining and disease-free survival was observed. A significant correlation, however, was seen between loss of BRMS1 protein expression and reduced disease-free survival when stratified by either loss of ER (P=0.008) or PR (P=0.029) or HER2 overexpression (P=0.026). Overall, there was poor correlation between BRMS1 protein staining and copy number status. CONCLUSIONS: These data suggest a mechanistic relationship between BRMS1 expression, hormone receptor status, and HER2 growth factor. BRMS1 staining could potentially be used in patient stratification in conjunction with other prognostic markers. Further, mechanisms other than genomic deletion account for loss of BRMS1 gene expression in breast tumors. 相似文献